Get the Stockscreener App
0.35
3.05%
-0.011
After Hours:
.36
0.01
+2.86%
Nexalin Technology Inc stock is traded at $0.35, with a volume of 65,780.
It is down -3.05% in the last 24 hours and down -33.17% over the past month.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
See More
Previous Close:
$0.361
Open:
$0.36
24h Volume:
65,780
Relative Volume:
0.08
Market Cap:
$7.54M
Revenue:
$275.60K
Net Income/Loss:
$-8.33M
P/E Ratio:
-0.7577
EPS:
-0.4619
Net Cash Flow:
$-5.40M
1W Performance:
+2.13%
1M Performance:
-33.17%
6M Performance:
-54.09%
1Y Performance:
-63.55%
1-Day Range:
$0.3463
$0.3682
1-Week Range:
$0.33
$0.40
52-Week Range:
$0.305
$2.00
Nexalin Technology Inc Stock (NXL) Company Profile
Name
Nexalin Technology Inc
Sector
Industry
Phone
(832) 260-0222
Address
1776 YORKTOWN, HOUSTON
Compare NXL vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NXL
Nexalin Technology Inc
|
0.35 | 7.11M | 275.60K | -8.33M | -5.40M | -0.4619 |
ABT
Abbott Laboratories
|
95.63 | 158.05B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
324.73 | 120.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.06 | 100.14B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.60 | 63.44B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
95.18 | 52.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Nexalin Technology Inc Stock (NXL) Latest News
Form PRE 14A Nexalin Technology Inc For: 29 June By Investing.com - Investing.com South Africa
Nexalin Technology (NXL) seeks shareholder votes for equity plan, reverse split - Stock Titan
NexaLine Technology Registers 1.2 Million Shares for Resale - Moomoo
Nexalin Technology Secures US Patent for Deep-Brain Stimulation Targeting Insomnia - Sleep Review
Nexalin Technology, Inc. Actuals & Estimates (NASDAQ:NXL) - TradingView
$Nexalin Technology (NXL.US)$ - Moomoo
Nexalin Technology Inc (NXLIW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NXL Forecast — Price Target — Prediction for 2027 - TradingView
Nexalin Technology Inc (NXL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NXL Stock Price, Quote & Chart - ChartMill
Nexalin Brazil sleep trial earns award at brain congress - Stock Titan
Nexalin Technology Inc (NXL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Nexalin Technology Inc (NXL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Exclusive: Nexalin Brazil trial shows benefits across anxiety, sleep and quality of life - MSN
Nexalin Technology, Inc. Financial Disclosures & SEC Filings - TradingView
NXL Should I Buy - Intellectia AI
Nexalin Technology Inc (NXL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nexalin Technology Inc (NXL) Institutional Confidence - TradingKey
Nexalin Technology Inc (NXL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nexalin Technology Inc (NXL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nexalin Technology Inc (NXL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nexalin Technology Inc (NXLIW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nexalin Technology Inc (NXLIW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nexalin Technology Inc (NXLIW) Institutional Confidence - TradingKey
Nexalin Technology Inc (NXLIW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nexalin Technology Adopts Second Amended and Restated Bylaws Effective June 16, 2026 - Minichart
Nexalin Technology Inc (NXLIW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Nexalin Overhauls Bylaws, Modernizes Corporate Governance Framework - TipRanks
Nexalin Technology (NXL) overhauls bylaws, lowers quorum and adds exclusive forum rules - Stock Titan
Nexalin Technology Inc (NXL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nexalin abstracts accepted at NYC neuromodulation conference By Investing.com - Investing.com South Africa
Nexalin Technology Inc (NXLIW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nexalin Technology Inc (NXLIW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nexalin Technology Inc (NXLIW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nexalin Technology Announces Acceptance of Two Clinical Abstracts for Presentation At 2026 Nyc Neuromodulation Conference - marketscreener.com
Nexalin abstracts accepted at NYC neuromodulation conference - Investing.com
Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life - Yahoo Finance
Nexalin Technology Inc. (NXL) Q1 2026 Earnings: EPS Misses Amid Continued Development PhaseEarnings Outlook Update - newsline.com
Nexalin reports positive results from anxiety disorder trial By Investing.com - Investing.com Nigeria
EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life - Sahm
Nexalin Technology, Inc. (NXL) stock price, news, quote and history - Yahoo Finance Australia
Nexalin Technology Q1 2026 Earnings: Wider-than-Expected Loss but Stock Gains 2%ROA Comparison - newsline.com
NXL Q1 2026 Earnings: EPS Misses Estimates, Stock Gains Despite Wider LossEarnings Surprise Score - newsline.com
Nexalin reports positive clinical trial results for anxiety and insomnia - grafa.com
Nexalin reports positive results from anxiety disorder trial - Investing.com UK
Nexalin Study Shows Strong Anxiety and Depression Response in Brazil Trial - Moomoo
Nexalin Technology, Inc. Reports Successful Clinical Trial Results for Non-Invasive Neurostimulation Treatment of Anxiety and Depression - Quiver Quantitative
Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sale - 富途牛牛
Nexalin receives U.S. patent for neurostimulation method - Investing.com UK
Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia - markets.businessinsider.com
Nexalin receives U.S. patent for neurostimulation method By Investing.com - Investing.com South Africa
Nexalin Technology Inc Stock (NXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.62%
2.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):